Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms like disorganized thinking or executive dysfunction. As a result, many ...

Researchers identify specific immune markers, like activated monocytes and cytokines, that drive cognitive decline after viral infections across various diseases.

Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.

Discover innovative schizophrenia treatment options targeting cognitive symptoms for improved patient independence.

Teachers College at Columbia University is set to offer its first neuroscience-focused doctoral program following the University Senate’s approval las.

Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms ...

Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to schizophrenia.

What impact does a viral infection have on our memory, attention, and concentration? The COVID-19 pandemic has reignited ...

Researchers link glymphatic system (brain waste-clearance) dysfunction in childhood to the future development of psychosis and chemical imbalances.

Substance use disorders are rarely, if ever, isolated concerns. Substance use is often a response to unaddressed mental health challenges, trauma, and unmet needs, and should be treated as such.

Over 22 million Americans are diagnosed with ADHD - yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive1 Firefly's AI-powered EEG/E ...